脑膜瘤新兴全身治疗选择
本文综述脑膜瘤全身治疗证据,通过PubMed检索文献并查询ClinicalTrials.gov在研试验。经典细胞毒药物、生长抑素类似物和抗激素治疗疗效有限;酪氨酸激酶抑制剂和单克隆抗体(如舒尼替尼、贝伐珠单抗)在小型2期试验中显示有前景的抗肿瘤活性;mTOR、FAK、CDK、PI3K、Sonic hedgehog信号及组蛋白去乙酰化酶抑制剂等新靶点正在研究中;免疫检查点抑制剂早期结果提示部分患者有临床意义的缓解。结论指出高级别证据匮乏,早期试验的积极信号需大型前瞻性对照试验确认。
要点
- 经典细胞毒药物、生长抑素类似物和抗激素治疗对脑膜瘤疗效有限。
- 舒尼替尼和贝伐珠单抗等抗血管生成药物在小型2期试验中显示有前景的抗肿瘤活性。
- mTOR、FAK、CDK、PI3K、Sonic hedgehog及HDAC抑制剂等新靶点正在研究中。
核心结论
- 脑膜瘤全身治疗缺乏高级别证据,但近十年发现了有趣的新治疗靶点。
- 抗血管生成药物、基因组靶向药物和免疫治疗在早期试验中的积极信号应在大规模前瞻性对照试验中确认。
研究设计与样本
- 通过PubMed检索脑膜瘤全身治疗现有文献,并通过ClinicalTrials.gov探索正在进行的临床试验。
主要发现
- 经典细胞毒药物、生长抑素类似物和抗激素治疗仅显示有限疗效。
- 酪氨酸激酶抑制剂和单克隆抗体,尤其是靶向血管生成信号者如舒尼替尼和贝伐珠单抗,在小型2期试验中显示有前景的抗肿瘤活性。
- 近期关于脑膜瘤(表)遗传改变的重要研究揭示了潜在治疗靶点,目前正在研究中。
- 评估伊匹木单抗、纳武利尤单抗、帕博利珠单抗和阿维鲁单抗等免疫检查点抑制剂的临床试验正在进行,早期结果提示部分患者有临床意义的缓解。
关键数值与推荐
- 潜在治疗靶点包括哺乳动物雷帕霉素靶蛋白(mTOR)、黏着斑激酶(FAK)、细胞周期蛋白依赖性激酶(CDK)、磷酸肌醇3-激酶(PI3K)、Sonic hedgehog信号及组蛋白去乙酰化酶抑制剂。
- 正在评估的免疫检查点抑制剂包括伊匹木单抗、纳武利尤单抗、帕博利珠单抗和阿维鲁单抗。
临床怎么用
- 原文未据此给出推荐。
局限性
- 脑膜瘤全身治疗缺乏高级别证据。
- 抗血管生成药物、基因组靶向药物和免疫治疗在早期试验中的积极信号应在大规模前瞻性对照试验中确认。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Meningiomas are the most frequently diagnosed intracranial neoplasms. Usually, they are treated by surgical resection in curative intent. Radiotherapy and stereotactic radiosurgery are commonly applied in the adjuvant setting in newly diagnosed atypical (CNS WHO grade 2), and anaplastic (CNS WHO grade 3) meningioma, especially if gross total resection is not feasible, and in recurrent cases. Conversely, the evidence for pharmacotherapy in meningioma is scarce. METHODS: The available literature of systemic treatment in meningioma was screened using PubMed, and ongoing clinical trials were explored using ClinicalTrials.gov. RESULTS: Classical cytotoxic agents, somatostatin analogs, and antihormone treatments have shown only limited efficacy. In contrast, tyrosine kinase inhibitors and monoclonal antibodies, especially those targeting angiogenic signaling such as sunitinib and bevacizumab, have shown promising antitumoral activity in small phase 2 trials. Moreover, results of recent landmark studies on (epi-)genetic alterations in meningioma revealed potential therapeutic targets which are currently under investigation. These include inhibitors of mammalian target of rapamycin (mTOR), focal adhesion kinase (FAK), cyclin-dependent kinases (CDK), phosphoinositide-3-kinase (PI3K), sonic hedgehog signaling, and histone deacetylases. In addition, clinical trials evaluating immune checkpoint inhibitors such as ipilimumab, nivolumab, pembrolizumab and avelumab are currently being conducted and early results suggest clinically meaningful responses in a subset of patients. CONCLUSIONS: There is a paucity of high-level evidence on systemic treatment options in meningioma. However, interesting novel treatment targets have been identified in the last decade. Positive signals of anti-angiogenic agents, genomically targeted agents and immunotherapy in early phase trials should be confirmed in large prospective controlled trials.
引用
- Mair MJ, Berghoff AS, Brastianos PK, et al. Emerging systemic treatment options in meningioma. J Neurooncol. 2022. PMID: 36181606. doi:10.1007/s11060-022-04148-8
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。